Building, scaling, and exiting healthcare businesses.
Charles Cornish — MBA · CPA · MIT AI in Healthcare
Twenty years building and exiting healthcare technology companies across the US, Australia, EU/UK, and Brazil. Most recently CEO and co-owner of Monarch Medical Technologies, strategic divestment 2025. Currently advising in precision oncology diagnostics and evaluating CEO or acquisition opportunities in PE-backed healthcare software.
Current focus
Distressed or underperforming healthcare software companies seeking a turnaround operator with a track record of exits.
Evaluating acquisition targets in precision oncology diagnostics with a view to PE-backed roll-up and exit.
Deep engagement with precision oncology and pharmacogenomics companies on commercialization, go-to-market, and deal structure.
Track record
- CEO and co-owner, Monarch Medical Technologies — strategic divestment 2025
- CEO and co-owner, DoseMeRx — strategic divestment 2018
- 20+ years operating across US, Australia, EU/UK, and Brazil
- Domain depth in clinical decision support, diagnostics commercialization, and AI-enabled health solutions
- Fluency in PE/VC deal structures, international markets, and SaaS/medtech operating models
Open to conversations.
PE firms, diagnostics companies, executive search, and strategic partners.